{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:46:24Z","timestamp":1789173984431,"version":"build-2803163510"},"reference-count":93,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jtha.2025.08.028","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T03:41:22Z","timestamp":1757648482000},"page":"3781-3790","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The hepatic Odyssey of Adeno-associated virus: from gene delivery to long-term outcomes"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5825-2927","authenticated-orcid":false,"given":"Giulia","family":"Simini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7808-3462","authenticated-orcid":false,"given":"Paul","family":"Batty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.08.028_bib1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jtha.2025.08.028_bib2","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1038\/nprot.2006.207","article-title":"Production and characterization of adeno-associated viral vectors","volume":"1","author":"Grieger","year":"2006","journal-title":"Nat Protoc"},{"key":"10.1016\/j.jtha.2025.08.028_bib3","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1089\/hum.2009.094","article-title":"Large-scale adeno-associated viral vector production using a herpesvirus-based system enables manufacturing for clinical studies","volume":"20","author":"Clement","year":"2009","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jtha.2025.08.028_bib4","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1089\/hum.2022.169","article-title":"Liver gene therapy","volume":"33","author":"Nathwani","year":"2022","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jtha.2025.08.028_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2019000007","article-title":"Gene therapy for hemophilia","volume":"2019","author":"Nathwani","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtha.2025.08.028_bib6","doi-asserted-by":"crossref","first-page":"5804","DOI":"10.1073\/pnas.94.11.5804","article-title":"Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus","volume":"94","author":"Herzog","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2025.08.028_bib7","doi-asserted-by":"crossref","first-page":"10222","DOI":"10.1128\/JVI.72.12.10222-10226.1998","article-title":"Adeno-associated virus as a vector for liver-directed gene therapy","volume":"72","author":"Xiao","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.jtha.2025.08.028_bib8","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1182\/blood.V99.8.2670","article-title":"Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy","volume":"99","author":"Mount","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.08.028_bib9","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1182\/blood-2008-10-181479","article-title":"Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy","volume":"113","author":"Niemeyer","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.08.028_bib10","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1182\/blood-2005-10-4035","article-title":"Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver","volume":"107","author":"Nathwani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.08.028_bib11","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2025.08.028_bib12","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1056\/NEJMoa2414783","article-title":"Sustained clinical benefit of AAV gene therapy in severe hemophilia B","volume":"392","author":"Reiss","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.08.028_bib13","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","article-title":"X-linked thrombophilia with a mutant factor IX (factor IX Padua)","volume":"361","author":"Simioni","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.08.028_bib14","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.08.028_bib15","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1182\/blood-2010-05-282707","article-title":"Codon optimization of human factor VIII cDNAs leads to high-level expression","volume":"117","author":"Ward","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.08.028_bib16","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood-2003-01-0292","article-title":"Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector","volume":"102","author":"Scallan","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.08.028_bib17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/blood-2005-12-5115","article-title":"Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs","volume":"108","author":"Jiang","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.08.028_bib18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41587-020-0741-7","article-title":"A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells","volume":"39","author":"Nguyen","year":"2021","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jtha.2025.08.028_bib19","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1182\/blood.2021014735","article-title":"Long-term follow-up of liver-directed, adeno-associated vector-mediated gene therapy in the canine model of hemophilia A","volume":"140","author":"Batty","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.08.028_bib20","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1182\/blood-2012-10-462200","article-title":"Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant","volume":"121","author":"McIntosh","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.08.028_bib21","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-factor VIII gene transfer in severe hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.08.028_bib22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.08.028_bib23","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s40265-022-01788-y","article-title":"Valoctocogene roxaparvovec: first approval","volume":"82","author":"Blair","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.jtha.2025.08.028_bib24","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40265-023-01845-0","article-title":"Etranacogene dezaparvovec: first approval","volume":"83","author":"Heo","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.jtha.2025.08.028_bib25","first-page":"1","article-title":"Adeno-associated virus biology","volume":"807","author":"Weitzman","year":"2011","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jtha.2025.08.028_bib26","doi-asserted-by":"crossref","first-page":"14793","DOI":"10.1128\/JVI.79.23.14793-14803.2005","article-title":"Characterization of adeno-associated virus genomes isolated from human tissues","volume":"79","author":"Schnepp","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.jtha.2025.08.028_bib27","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1002\/j.1460-2075.1991.tb04964.x","article-title":"Targeted integration of adeno-associated virus (AAV) into human chromosome 19","volume":"10","author":"Samulski","year":"1991","journal-title":"EMBO J"},{"key":"10.1016\/j.jtha.2025.08.028_bib28","doi-asserted-by":"crossref","first-page":"7951","DOI":"10.1128\/jvi.71.10.7951-7959.1997","article-title":"Adeno-associated virus Rep proteins target DNA sequences to a unique locus in the human genome","volume":"71","author":"Surosky","year":"1997","journal-title":"J Virol"},{"key":"10.1016\/j.jtha.2025.08.028_bib29","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ymthe.2006.05.009","article-title":"Adeno-associated virus serotypes: vector toolkit for human gene therapy","volume":"14","author":"Wu","year":"2006","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2025.08.028_bib30","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/gt.2012.6","article-title":"Intracellular transport of recombinant adeno-associated virus vectors","volume":"19","author":"Nonnenmacher","year":"2012","journal-title":"Gene Ther"},{"key":"10.1016\/j.jtha.2025.08.028_bib31","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0092-8674(83)90342-2","article-title":"Rescue of adeno-associated virus from recombinant plasmids: gene correction within the terminal repeats of AAV","volume":"33","author":"Samulski","year":"1983","journal-title":"Cell"},{"key":"10.1016\/j.jtha.2025.08.028_bib32","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1128\/JVI.72.4.3241-3247.1998","article-title":"In vitro packaging of adeno-associated virus DNA","volume":"72","author":"Zhou","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.jtha.2025.08.028_bib33","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1128\/JVI.72.2.1438-1445.1998","article-title":"Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions","volume":"72","author":"Summerford","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.jtha.2025.08.028_bib34","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1172\/JCI57367","article-title":"The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice","volume":"121","author":"Bell","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtha.2025.08.028_bib35","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.tim.2021.09.005","article-title":"Adeno-associated virus (AAV) cell entry: structural insights","volume":"30","author":"Meyer","year":"2022","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.jtha.2025.08.028_bib36","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.coviro.2017.06.003","article-title":"Host determinants of adeno-associated viral vector entry","volume":"24","author":"Pillay","year":"2017","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.jtha.2025.08.028_bib37","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.molmed.2020.09.010","article-title":"Journey to the center of the cell: tracing the path of AAV transduction","volume":"27","author":"Dhungel","year":"2021","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.jtha.2025.08.028_bib38","doi-asserted-by":"crossref","first-page":"11040","DOI":"10.1128\/JVI.01056-06","article-title":"Adeno-associated virus type 2 capsids with externalized VP1\/VP2 trafficking domains are generated prior to passage through the cytoplasm and are maintained until uncoating occurs in the nucleus","volume":"80","author":"Sonntag","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.jtha.2025.08.028_bib39","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/sj.gt.3302527","article-title":"Intracellular trafficking of adeno-associated viral vectors","volume":"12","author":"Ding","year":"2005","journal-title":"Gene Ther"},{"key":"10.1016\/j.jtha.2025.08.028_bib40","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ymthe.2019.11.005","article-title":"GPR108 is a highly conserved AAV entry factor","volume":"28","author":"Dudek","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2025.08.028_bib41","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1128\/JVI.77.6.3495-3504.2003","article-title":"Genetic fate of recombinant adeno-associated virus vector genomes in muscle","volume":"77","author":"Schnepp","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.jtha.2025.08.028_bib42","doi-asserted-by":"crossref","first-page":"8568","DOI":"10.1128\/JVI.72.11.8568-8577.1998","article-title":"Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue","volume":"72","author":"Duan","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.jtha.2025.08.028_bib43","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.ymthe.2022.06.004","article-title":"Evaluating the state of the science for adeno-associated virus integration: an integrated perspective","volume":"30","author":"Sabatino","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2025.08.028_bib44","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/s41587-023-01974-7","article-title":"Integrated vector genomes may contribute to long-term expression in primate liver after AAV administration","volume":"42","author":"Greig","year":"2023","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jtha.2025.08.028_bib45","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1016\/j.jtha.2024.07.012","article-title":"Adeno-associated viral vector integration: implications for long-term efficacy and safety","volume":"22","author":"Batty","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.08.028_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2019.103997","article-title":"TLR9 signaling mediates adaptive immunity following systemic AAV gene therapy","volume":"346","author":"Ashley","year":"2019","journal-title":"Cell Immunol"},{"key":"10.1016\/j.jtha.2025.08.028_bib47","doi-asserted-by":"crossref","first-page":"5915","DOI":"10.1128\/JVI.00500-16","article-title":"Diminished innate antiviral response to adenovirus vectors in cGAS\/STING-deficient mice minimally impacts adaptive immunity","volume":"90","author":"Anghelina","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.jtha.2025.08.028_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.975803","article-title":"Immunogenicity and toxicity of AAV gene therapy","volume":"13","author":"Ertl","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2025.08.028_bib49","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1128\/JVI.01990-07","article-title":"Complement is an essential component of the immune response to adeno-associated virus vectors","volume":"82","author":"Zaiss","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.jtha.2025.08.028_bib50","first-page":"3879","article-title":"Next-generation strategies to improve safety and efficacy of adeno-associated virus-based gene therapy for hemophilia: lessons from clinical trials in other gene therapies","volume":"109","author":"Di Minno","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2025.08.028_bib51","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1089\/hum.2024.156","article-title":"Thrombotic microangiopathy associated with systemic adeno-associated virus gene transfer: review of reported cases","volume":"36","author":"Laforet","year":"2025","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jtha.2025.08.028_bib52","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/j.ekir.2024.04.024","article-title":"Thrombotic microangiopathy as an emerging complication of viral vector-based gene therapy","volume":"9","author":"Schwotzer","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.jtha.2025.08.028_bib53","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1089\/hum.2023.194","article-title":"Complement system response to adeno-associated virus vector gene therapy","volume":"35","author":"Kropf","year":"2024","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jtha.2025.08.028_bib54","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.ymthe.2024.02.002","article-title":"High-dose systemic adeno-associated virus vector administration causes liver and sinusoidal endothelial cell injury","volume":"32","author":"Hordeaux","year":"2024","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2025.08.028_bib55","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/595830","article-title":"Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses","volume":"199","author":"Calcedo","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jtha.2025.08.028_bib56","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum Gene Ther"},{"issue":"Pt 2","key":"10.1016\/j.jtha.2025.08.028_bib57","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1099\/vir.0.035113-0","article-title":"Examining the cross-reactivity and neutralization mechanisms of a panel of mAbs against adeno-associated virus serotypes 1 and 5","volume":"93","author":"Harbison","year":"2012","journal-title":"J Gen Virol"},{"key":"10.1016\/j.jtha.2025.08.028_bib58","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40259-023-00585-7","article-title":"Immunogenicity of recombinant adeno-associated virus (AAV) vectors for gene transfer","volume":"37","author":"Arjomandnejad","year":"2023","journal-title":"BioDrugs"},{"key":"10.1016\/j.jtha.2025.08.028_bib59","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/mt.2012.84","article-title":"Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B","volume":"20","author":"Mingozzi","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2025.08.028_bib60","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005795","article-title":"Overcoming preexisting humoral immunity to AAV using capsid decoys","volume":"5","author":"Mingozzi","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtha.2025.08.028_bib61","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-020-0911-7","article-title":"IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies","volume":"26","author":"Leborgne","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2025.08.028_bib62","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1182\/bloodadvances.2017010181","article-title":"Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors","volume":"1","author":"Meliani","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.08.028_bib63","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2006-04-017913","article-title":"Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy","volume":"108","author":"Jiang","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.08.028_bib64","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.omtm.2019.05.009","article-title":"Therapeutic hFIX activity achieved after single AAV5-hFIX treatment in hemophilia B patients and NHPs with pre-existing anti-AAV5 NABs","volume":"14","author":"Majowicz","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtha.2025.08.028_bib65","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/bloodadvances.2019000811","article-title":"Etranacogene dezaparvovec (AMT-061 phase 2b): normal\/near normal FIX activity and bleed cessation in hemophilia B","volume":"3","author":"Von Drygalski","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.08.028_bib66","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1182\/bloodadvances.2023010511","article-title":"Hemophilia B and gene therapy: a new chapter with etranacogene dezaparvovec","volume":"8","author":"Anguela","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.08.028_bib67","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nm1549","article-title":"CD8(+) T-cell responses to adeno-associated virus capsid in humans","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2025.08.028_bib68","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood.2019004625","article-title":"BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression","volume":"137","author":"Konkle","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.08.028_bib69","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1172\/JCI68205","article-title":"CpG-depleted adeno-associated virus vectors evade immune detection","volume":"123","author":"Faust","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtha.2025.08.028_bib70","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ymthe.2020.01.026","article-title":"Codon modification and PAMPs in clinical AAV vectors: the tortoise or the hare?","volume":"28","author":"Wright","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2025.08.028_bib71","article-title":"The presence of CpGs in AAV gene therapy vectors induces a plasmacytoid dendritic cell-like population very early after administration","volume":"399\u2013400","author":"Glenn","year":"2024","journal-title":"Cell Immunol"},{"key":"10.1016\/j.jtha.2025.08.028_bib72","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.omtm.2021.10.010","article-title":"Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells","volume":"23","author":"Arjomandnejad","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtha.2025.08.028_bib73","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1172\/JCI70314","article-title":"Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression","volume":"123","author":"Mueller","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtha.2025.08.028_bib74","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1182\/blood.2023023275","article-title":"Coagulation factor VIII: biological basis of emerging hemophilia A therapies","volume":"144","author":"Samelson-Jones","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.08.028_bib75","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","article-title":"Lethal immunotoxicity in high-dose systemic AAV therapy","volume":"31","author":"Duan","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2025.08.028_bib76","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1089\/hum.2009.060","article-title":"Adeno-associated virus-mediated gene transfer to nonhuman primate liver can elicit destructive transgene-specific T cell responses","volume":"20","author":"Gao","year":"2009","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jtha.2025.08.028_bib77","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/87551225221116266","article-title":"Complications of corticosteroid therapy: a comprehensive literature review","volume":"38","author":"Koshi","year":"2022","journal-title":"J Pharm Technol"},{"key":"10.1016\/j.jtha.2025.08.028_bib78","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13023-022-02256-2","article-title":"The experiences of people with haemophilia and their families of gene therapy in a clinical trial setting: regaining control, the Exigency study","volume":"17","author":"Fletcher","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jtha.2025.08.028_bib79","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.omtm.2019.12.008","article-title":"Immune response mechanisms against AAV vectors in animal models","volume":"17","author":"Martino","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtha.2025.08.028_bib80","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/hae.15125","article-title":"UKHCDO gene therapy taskforce: Guidance for implementation of haemophilia gene therapy into routine clinical practice for adults","volume":"31","author":"Chowdary","year":"2025","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.08.028_bib81","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1182\/bloodadvances.2024013059","article-title":"Optimizing liver health before and after gene therapy for hemophilia A","volume":"8","author":"Ragni","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.08.028_bib82","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/hematology.2022000388","article-title":"Gene therapy for hemophilia","volume":"2022","author":"Nathwani","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtha.2025.08.028_bib83","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1182\/bloodadvances.2023011847","article-title":"Roctavian gene therapy for hemophilia A","volume":"8","author":"Samelson-Jones","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.08.028_bib84","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-med-043021-033013","article-title":"Adeno-associated virus gene therapy for hemophilia","volume":"74","author":"Samelson-Jones","year":"2023","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jtha.2025.08.028_bib85","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1128\/JVI.75.15.6969-6976.2001","article-title":"Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo","volume":"75","author":"Nakai","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.jtha.2025.08.028_bib86","series-title":"International Society on Thrombosis and Haemostasis","article-title":"Mechanisms of AAV vector persistence following infant gene therapy in severe hemophilia A dogs","author":"Batty","year":"2025"},{"key":"10.1016\/j.jtha.2025.08.028_bib87","series-title":"International Society on Thrombosis and Haemostasis","article-title":"Safe multi-year bleeding reduction by AAV gene therapy in neonatal and juvenile hemophilia B dogs","author":"Merricks","year":"2025"},{"key":"10.1016\/j.jtha.2025.08.028_bib88","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ymthe.2019.12.009","article-title":"Retroviral insertional mutagenesis in humans: evidence for four genetic mechanisms promoting expansion of cell clones","volume":"28","author":"Bushman","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2025.08.028_bib89","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ng.3389","article-title":"Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas","volume":"47","author":"Nault","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtha.2025.08.028_bib90","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1186\/s12864-021-08098-9","article-title":"Integration of adeno-associated virus (AAV) into the genomes of most Thai and Mongolian liver cancer patients does not induce oncogenesis","volume":"22","author":"Sch\u00e4ffer","year":"2021","journal-title":"BMC Genomics"},{"key":"10.1016\/j.jtha.2025.08.028_bib91","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1126\/science.1142658","article-title":"AAV vector integration sites in mouse hepatocellular carcinoma","volume":"317","author":"Donsante","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.jtha.2025.08.028_bib92","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/mt.2016.52","article-title":"Recombinant AAV integration is not associated with hepatic genotoxicity in nonhuman primates and patients","volume":"24","author":"Gil-Farina","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2025.08.028_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101294","article-title":"The longitudinal kinetics of AAV5 vector integration profiles and evaluation of clonal expansion in mice","volume":"32","author":"Ismail","year":"2024","journal-title":"Mol Ther Methods Clin Dev"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625005537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625005537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T23:21:51Z","timestamp":1763767311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625005537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":93,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1538783625005537"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.08.028","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The hepatic Odyssey of Adeno-associated virus: from gene delivery to long-term outcomes","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.08.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}